|
|
|
|
|
|
|
06.05.26 - 14:06
|
Timothy P. Walbert Joins Patient Square Capital as a Senior Advisor (Business Wire)
|
|
|
MENLO PARK, Calif.--(BUSINESS WIRE)--Patient Square Capital, a leading health care investment firm, today announced that Timothy P. Walbert has joined the firm as a Senior Advisor.
Mr. Walbert brings more than three decades of biopharmaceutical leadership experience and currently serves as Managing Partner of HRZN Partners LLC and a Senior Advisor to Amgen. Most recently, he was Chairman, President, and Chief Executive Officer of Horizon Therapeutics, which he grew to approximately $4 billion in annual sales prior to its $28.3 billion acquisition by Amgen in 2023; earlier, he led IDM Pharma Inc. through its acquisition by Takeda and held senior roles at Abbott (now AbbVie), where he led the global launch of HUMIRA®, as well as at G.D. Searle & Company, Merck & Co., and Wyeth.
“Patient Square Capital has built a highly differentiated platform and a strong record of partnering with management teams to create enduring value in health care,” said Tim Walbert. “I'm pleased to join the firm as a Senior ...
|
|
|
05.05.26 - 19:24
|
Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds (24/7 Wall St.)
|
|
|
Merck (NYSE:MRK) delivered its fourth consecutive earnings beat, but shares slipped on the earnings report. With acquisition charges clouding the quarter, here is where the stock heads next. The 24/7 Wall St. Price Target for Merck Is $135.70 Our 24/7 Wall St. price target for Merck is $135.70 over the next 12 months, implying 24.29% ... Merck Stock Looks Undervalued as KEYTRUDA Growth and Pipeline Offset Near-Term Headwinds...
|
|
|
05.05.26 - 14:48
|
Merck Completes Acquisition of Terns Pharmaceuticals, Inc. (Business Wire)
|
|
|
Addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck's oncology pipelineRAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the acquisition of Terns Pharmaceuticals, Inc. (“Terns”) (Nasdaq: TERN).
“The Terns acquisition reflects Merck's continued focus on science‑driven, value‑enhancing business development aimed at bringing meaningful innovation to patients,” said Robert M. Davis, chairman and chief executive officer, Merck. “We believe TERN‑701 has the potential to become a differentiated treatment option for certain patients with chronic myeloid leukemia, and we look forward to working with the Terns team to advance its clinical development.”
TERN-701 was recently granted Breakthrough Therapy Designation (BTD) by the U.S. Food and Drug Administration (FDA) for the treatment of adults with Philadelphia chromosome-posi...
|
|
|
|
|
|
|
|
|
30.04.26 - 17:36
|
Merck & Co Aktie: Operatives Geschäft stärker als erwartet (Aktiencheck)
|
|
|
Wien (www.aktiencheck.de) - Merck & Co-Aktienanalyse der Raiffeisen Bank International AG:
Julian Lindinger, Analyst der Raiffeisen Bank International AG (RBI), nimmt in einer aktuellen Aktienanalyse die Aktie von Merck & Co Inc. (ISIN: US58933Y1055, WKN: A0YD8Q, Ticker-Symbol: 6MK, NYSE-Symbol: MRK) unter die Lupe. [mehr]...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
30.04.26 - 12:36
|
Merck & Co., Inc., Rahway, N.J., USA Announces First-Quarter 2026 Financial Results; Highlights Significant Regulatory Approvals and Clinical Milestones (Business Wire)
|
|
|
Sales Growth Driven by Continued Strength in Oncology and Animal Health, Plus Increasing Contributions From Launches
Total Worldwide Sales Were $16.3 Billion (5% Growth; 3% Growth ex-FX)
KEYTRUDA/KEYTRUDA QLEX1 Sales Were $8.0 Billion (12% Growth; 8% Growth ex-FX); Includes KEYTRUDA QLEX Sales of $128 Million
WINREVAIR Sales Were $525 Million (88% Growth; 87% Growth ex-FX)
Animal Health Sales Were $1.8 Billion (13% Growth; 6% Growth ex-FX)
GAAP Loss per Share Was $1.72; Non-GAAP Loss per Share Was $1.28; GAAP and Non-GAAP Loss per Share Include a Charge of $3.62 per Share for the Acquisition of Cidara
Presented New Data From Cardio-Pulmonary Pipeline at ACC.26, Including Positive Results From Phase 3 CORALreef AddOn Trial
Received U.S. FDA Approval for IDVYNSO, a Once-Daily, Oral Treatment for Certain Adults With Virologically Suppressed HIV-1
Achieved Multiple Significant Regulatory and Clinical Milestones Across Oncology Pipeline
Announced Agreement To Acquire Terns Pharmaceuticals, Inc. and Expand Hema...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
